Navigation Links
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Date:5/20/2009

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies

BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a drug-eluting stent.

Presented by Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, two year follow up data from the single center TRIAS HR (high risk) study show similar mortality (5.1% vs 4.2%) and target lesion revascularization (TLR) rates (15.3% vs 13.7%) for the Genous Bio-engineered R stent compared to Boston Scientific's Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% to 5.3%, with another event occurring at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. There were no thrombotic events in the Genous treated group at any time period (0.0%). Myocardial infarctions (MI) increased from years one to two in the Taxus patients to 6.3%, while the MI rate in the Genous patients remained steady at 3.1%, all of which were peri-procedural.

"While both groups of patients showed good clinical outcomes, the Genous treated patients were relatively stable between one and two years," said Beijk.

TRIAS HR is a randomized, 193-patient, single-center, prospective study involving patients with a high risk of restenosis. High risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than or equal to 2.8 mm) and/or long lesions (greater than or equal to 23
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
2. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
3. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
4. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
5. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
6. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
11. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... , September 17, 2014 According ... by Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), ... & Wellness), and by Geography - Global Forecast to ... electronics market is expected to reach $56.50 Billion by ... to 2020. Browse 235 market data Tables ...
(Date:9/17/2014)... CITY, Utah , Sept. 17, 2014 /PRNewswire/ ... an exclusive global licensing and collaboration agreement with ... and commercialize NuView,s investigative genomic-based diagnostic biomarker to ... agreement also includes all other future diagnostic-imaging applications. ... for in-vivo therapeutic delivery and in-vitro urine screen ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... WORCESTER, Mass. and TORONTO, May 17, 2012  Generex ... today that new members have joined the Scientific ... Express, Inc. for the company,s AE37 breast cancer ... N. Hortobagyi, MD, FACP (University of Texas MD ...
... TUCSON, Ariz., May 17, 2012 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... March 31, 2012, due in part to Certified Centers ... SynCardia temporary Total Artificial Heart . ...
Cached Medicine Technology:Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 2Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 3Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 4SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3
(Date:9/17/2014)... News) -- Managing diabetes, quitting smoking, controlling high blood ... the risk for dementia -- even late in life, ... Report 2014, commissioned by Alzheimer,s Disease International, revealed that ... percent. The study noted that obesity and an inactive ... as high blood pressure. The researchers suggested ...
(Date:9/17/2014)... an analysis of genetic information among more than 87,000 ... found 23 new genetic variants common differences in ... for prostate cancer. The so-called "meta-analysis," believed to be ... mutations among men in a broad array of ethnic ... ancestry. , The meta-analysis combined information from smaller studies, ...
(Date:9/17/2014)... In a country where 77% of inhabitants ... basis, how can Americans find healthy and fulfilling ways ... Challenge , a 5-day interactive journey to putting stress ... From September 29th – October 3rd, the Hyland’s Stress ... specific topics that promote natural solutions for managing stress. ...
(Date:9/17/2014)... that patients with human papillomavirus (HPV) the ... and neck cancer positive oropharyngeal cancer see ... post-radiation neck dissection than those with HPV-negative oropharyngeal ... findings at the American Society for Radiation Oncology,s ... , "For patients that achieve a complete response, ...
(Date:9/17/2014)... People with facial paralysis are perceived as being less ... language of facial expression, a new study from an ... findings highlight the important role the face plays in ... against those with facial paralysis because of their disability, ... the College of Liberal Arts at Oregon State University. ...
Breaking Medicine News(10 mins):Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Large study reveals new genetic variants that raise risk for prostate cancer 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Many throat cancer patients can skip neck surgery 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3
... for the first time that human embryonic stem cells ... mature T-cells//, raising hopes for a gene therapy to ... and the Institute for Stem Cell Biology and Medicine ... embryonic stem cells into blood-forming stem cells that in ...
... recent survey it was found that international nurses would need to ... NHS//. ,The step was mainly taken to give jobs ... nurses come to Britain from outside the European Union every year. ... the Philippines and Australia. The rule applies to nurses in bands ...
... 45 seconds, another American has a stroke, caused either by a ... minutes//, one of them will die. ,That's the bad news. ... to find and fix the problems that cause many strokes — ... ever having to open up the skull. ,New technologies, ...
... Dr. Bing-Huei Chen and colleagues it was found that ... form during cooking. ,The research was conduced ... Products (COPs) is produced when cholesterol-rich foods are processed ... the body cells leading to heart disease or cancer. ...
... California Supreme Court said that partners must inform their spouse about ... ,This came down as the court ruling in San Francisco when ... court. The wife accused the ex-husband of transmitting AIDS to her. ... decided that the spouse or partner of a person who has ...
... from the Korea Research Institute of Bioscience and Biotechnology//. ... found a human gene that aids in the growth and spread ... about the discovery and said that it would help in the ... was mainly conducted on mice and the research team found that ...
Cached Medicine News:Health News:T-cells Developed from Human Embryonic Stem Cells 2Health News:Brain Surgery Without the Surgery? 2Health News:Brain Surgery Without the Surgery? 3Health News:Brain Surgery Without the Surgery? 4Health News:Brain Surgery Without the Surgery? 5Health News:Brain Surgery Without the Surgery? 6
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: